Table 2.
Basic information of twins and triplets.
| Twins |
GA (weeks) |
BW (g) |
MZ/ DZ |
Diagnose | Antenatal antibiotics | Time FI diagnosed (d) | Time FI recovered (d) |
Sample (n) |
|---|---|---|---|---|---|---|---|---|
| 1A | 29.1 | 980 | MZ | FI | None | 3 | 8 | 3 |
| 1B | 29.1 | 1,380 | MZ | FT | None | – | 3 | |
| 2A | 30 | 760 | MZ | FT | None | – | 5 | |
| 2B | 30 | 1,185 | MZ | FI | None | 2 | 8 | 5 |
| 3A | 28.6 | 1,330 | DZ | FT | Cefuroxime | – | 4 | |
| 3B | 28.6 | 1,350 | DZ | FI | Cefuroxime | 3 | 7 | 4 |
| 4A | 30.2 | 960 | DZ | FT | None | – | 4 | |
| 4B | 30.2 | 1,440 | DZ | FI | None | 2 | 8 | 4 |
| 5B | 30.6 | 1,600 | DZ | FT | None | – | 4 | |
| 5C | 30.6 | 1,655 | DZ | FI | None | 1 | 5 | 4 |
| 6A | 33.1 | 1,490 | DZ | FT | None | – | 2 | |
| 6B | 33.1 | 1,600 | DZ | FT | None | – | 2 | |
| 7A | 32.1 | 1,540 | MZ | FT | None | – | 3 | |
| 7B | 32.1 | 1,800 | MZ | FT | None | – | 3 | |
| 8A | 31.5 | 1,380 | DZ | FI | None | 2 | 6 | 4 |
| 8B | 31.5 | 1,315 | DZ | FT | None | – | 4 | |
| 8C | 31.5 | 760 | DZ | FI | None | 3 | 7 | 4 |
| 9A | 29 | 1,135 | DZ | FT | latamoxef | 3 | 6 | 4 |
| 9B | 29 | 1,045 | DZ | FI | latamoxef | – | 4 | |
| 10A | 33.1 | 1,706 | MZ | FT | None | – | 2 | |
| 10B | 33.1 | 1,750 | MZ | FT | None | – | 2 | |
| 11A | 29.3 | 1,040 | MZ | FI | None | 4 | 8 | 4 |
| 11B | 29.3 | 1,000 | MZ | FT | None | – | 4 |
GA, gestational age; BW, birth weight; MZ, monozygotic; DZ, dizygotic; FI, feeding intolerance; FT, feeding tolerance.